Company Exicure, Inc.

Equities

XCUR

US30205M2008

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-25 pm EDT			5-day change	1st Jan Change
0.509 ^USD	-1.17%		-12.06%	-12.29%

Mar. 22	North American Morning Briefing : Stocks Struggle After New Records	DJ
Feb. 29	An unknown buyer agreed to acquire 39.3% stake in Exicure, Inc. from DGP Co.,Ltd. for KRW 6 billion.	CI

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.

Number of employees: 7

USD in Million	2021	Weight	2022	Weight	Delta
Immuno-oncology Therapeutics 100.0 %	0	100.0 %	29	100.0 %	-6,068.12%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	0	100.0 %	29	100.0 %	-6,068.12%

Managers	Title	Age	Since
Paul Kang CEO	Chief Executive Officer	63	23-02-23
Ji-Young Hwang DFI	Director of Finance/CFO	47	22-11-30
Rebecca J. Peterson IRC	Investor Relations Contact	47	-
Joshua Miller AUD	Comptroller/Controller/Auditor	48	22-03-31

Members of the board	Title	Age	Since
Ji-Young Hwang DFI	Director of Finance/CFO	47	22-11-30
Paul Kang CEO	Chief Executive Officer	63	23-02-23
Hyuk Joon Ko BRD	Director/Board Member	-	23-08-22
Dongho Lee BRD	Director/Board Member	-	23-08-20
Hojoon Lee BRD	Director/Board Member	-	23-08-22
Minhee Eom BRD	Director/Board Member	-	23-09-25

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	8,648,307	4,753,248 ( 54.96 %)	0	54.96 %

Name	Equities	%	Valuation
CBI CO., LTD. 9.462 %	818,299	9.462 %	491 798 $
Abingworth LLP 3.257 %	281,636	3.257 %	169 263 $
Millennium Management LLC 0.6685 %	57,815	0.6685 %	34 747 $
Aescap Venture Management BV 0.6533 %	56,500	0.6533 %	33 957 $
Geode Capital Management LLC 0.6128 %	52,996	0.6128 %	31 851 $
Northwestern University 0.6030 %	52,145	0.6030 %	31 339 $
Renaissance Technologies LLC 0.5724 %	49,500	0.5724 %	29 750 $
Vanguard Group, Inc. (Subfiler) 0.4636 %	40,093	0.4636 %	24 096 $
Virtu Financial LLC 0.2159 %	18,674	0.2159 %	11 223 $
Two Sigma Securities LLC 0.1934 %	16,726	0.1934 %	10 052 $

Exicure, Inc.

2430 North Halsted Street

60614, Chicago

+847 673 1700

http://www.exicuretx.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
EXICURE, INC.	-12.29%	4.4M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.37%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs